Establishment and Validation of a Stable, Cell-Based Diabetic Wound Bioassay

皮肤伤口愈合延迟和足部溃疡影响高达15%的糖尿病患者。这种受损的皮肤伤口愈合被归因于皮肤细胞的变化，这些细胞可能会因疾病而改变。目前，没有合适的糖尿病创面模型存在，因此经常进行不适当的动物模型和人体试验。该项目将开发一种简单的、可重复的、基于实验室的糖尿病伤口模型系统，以允许快速、低成本地测试材料、试剂和药物，并重要地减少不必要的动物实验。我们已经从患者身上分离出正常和患病的(糖尿病)细胞，对它们进行改造，使它们永远生长，并识别出糖尿病伤口疾病的标记基因。这个新项目将使用这些疾病标记基因来开发一个基于细胞的报告系统，使自动化测试和试剂预筛选能够改善糖尿病伤口疾病的状态。我们的目标是将这种生物检测方法商业化，生产一种高通量筛选系统，以减少在伤口产品/材料测试方面进行的不必要的动物研究。

Delayed skin wound healing and foot ulcers affect up to 15% of diabetic patients. This impaired skin wound healing has been attributed to changes in the cells of the skin which may be altered by the disease. Currently, no suitable diabetic wound model exists and so inadequate animal models and human testing are often undertaken. This project will develop a simple, reproducible, laboratory-based diabetic wound model system to permit rapid, low cost testing of materials, reagents and drugs and importantly reduce unnecessary animal experimentation. We have already isolated normal and diseased (diabetic) cells from patients, altered them so that they grow forever and identified diabetic wound disease marker genes. This new project will use these disease marker genes to develop a cell-based reporter system, enabling automated testing and pre-screening of reagents which may ameliorate the diabetic wound disease state. It is our aim to develop this bioassay commercially, producing a high-throughput screening system which will reduce the amount of unnecessary animal studies undertaken with respect to wound products/materials testing.